Suzuki, Sayo

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 医療薬学・社会連携センター 医療薬学部門 (Shiba-Kyoritsu)

Position

Professor

Career 【 Display / hide

  • 2020.04
    -
    Present

    Keio University, Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Professor

  • 2017.04
    -
    2020.03

    Keio University, Division of Pharmaceutical Care Sciences, Faculty of Pharmacy, Associate Professor

  • 2010.01
    -
    2017.03

    慶應義塾大学, 薬学部医療薬学センター, 専任講師

  • 2009.04
    -
    2009.12

    慶應義塾大学, 医学部臨床薬剤学講座, 助教

  • 2007.04
    -
    2009.03

    慶應義塾大学, 医学部薬剤部, 助教

display all >>

Academic Background 【 Display / hide

  •  

    Kyoto University, 薬学研究科

    Graduate School, Completed, Master's course

  •  

    Kyoto University, 薬学部, 薬学科

    University, Graduated

Academic Degrees 【 Display / hide

  • 薬学修士, 京都大学, Coursework

    ラットにおけるCisplatinの腎排泄挙動と毒性

  • 博士(医学), Keio University, Dissertation, 2013.10

    S100A10 protein expression is associated with oxaliplatin sensitivity in human colorectal cancer cells.

Licenses and Qualifications 【 Display / hide

  • 薬剤師免許, 1989

  • 高等学校教諭二級普通免許(理科), 1989

  • 高等学校教諭専修免許(理科), 1991

 

Research Areas 【 Display / hide

  • Life Science / Clinical pharmacy (Clinical Pharmacology)

Research Keywords 【 Display / hide

  • Personalized Medicine

  • 医学・薬学教育

 

Books 【 Display / hide

  • 今日の治療指針 2022年度版

    Suzuki Sayo, Tanigawara Yusuke., 医学書院,東京, 2022.01

    Scope: Therapeutic Drug Monitoring

  • 今日の臨床サポート 改訂第4版

    清宮 啓介, 鈴木 小夜, エルゼビア・ジャパン株式会社, 2021.04

    Scope: 小児薬用量の考え方と小児薬物療法における注意点(小児科)

  • 今日の臨床サポート 改訂第4版

    西村 あや子, 鈴木 小夜, エルゼビア・ジャパン株式会社, 2021.02

    Scope: 授乳婦への薬物投与

  • 今日のOTC薬 -解説と便覧- (改訂第5版)

    Sayo Suzuki, 南江堂, 東京, 2021.02,  Page: 689

    Scope: 26. 強心薬,  Contact page: 486-493

  • 今日のOTC薬 -解説と便覧-(改訂第5版)

    Sayo Suzuki, 南江堂, 東京, 2021.02,  Page: 689

    Scope: 17. やけど用薬,  Contact page: 390-397

display all >>

Papers 【 Display / hide

  • Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high-performance liquid chromatography–Photodiode array detection

    Yokoyama Y., Nozawa E., Morita M., Ishikawa E., Mori T., Sakurai M., Kikuchi T., Matsuki E., Yamazaki R., Kataoka K., Jibiki A., Kawazoe H., Suzuki S., Nakamura T.

    Journal of Clinical Laboratory Analysis (Journal of Clinical Laboratory Analysis)     e24598 2022.07

    ISSN  08878013

     View Summary

    Background: Dasatinib, nilotinib, and bosutinib, second-generation tyrosine kinase inhibitors (TKIs), and ponatinib, a third-generation TKI, are approved pharmaceuticals used in the treatment of chronic myeloid leukemia (CML). Although liquid chromatography-tandem mass spectrometry assays for simultaneous quantification of the four TKIs in human serum have been reported in the literature, a high-performance liquid chromatography (HPLC) assay that simultaneously quantifies these compounds has not yet been developed. This study aims to establish and validate an efficient HPLC analytical method using a photodiode array (PDA) detector for the simultaneous quantification of the four TKIs. Methods: Calibration standards were prepared by serial dilution of serum samples containing the four TKIs, followed by solid-phase extraction. The four TKIs were eluted in order within 10 min using a binary HPLC gradient system. Results: The calibration ranges were 2–500 ng/ml for dasatinib, 100–5000 ng/ml for nilotinib, and 10–500 ng/ml for bosutinib and ponatinib. Intra-day and inter-day precision and accuracy values were found to be in accordance with the U.S. Food and Drug Administration guidelines. The recovery rates were 92.9%–96.0%, 80.7%–86.1%, 91.6%–99.0%, and 86.4%–92.6% for dasatinib, nilotinib, bosutinib, and ponatinib, respectively. Conclusion: To the best of our knowledge, this is the first report of an HPLC-PDA analytical method that allows efficient simultaneous quantification of the four TKIs in the serum of patients with CML. We believe that the method developed herein can improve the efficiency of therapeutic drug monitoring in patients with CML in clinical practice.

  • Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum.

    Ishikawa E, Yokoyama Y, Chishima H, Kuniyoshi O, Sato I, Nakaya N, Nakajima H, Kimura M, Hakamata J, Suehiro N, Nakada H, Ikemura S, Jibiki A, Kawazoe H, Muramatsu H, Suzuki S, Nakamura T

    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences)  1199   123245 2022.05

    ISSN  1570-0232

     View Summary

    Reports on the therapeutic drug monitoring (TDM) of second- and third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer patients are limited and are required to improve the safety of EGFR-TKI therapy. Some EGFR-TKIs have active metabolites with similar or higher potency compared with the parent compounds; thus, monitoring the parent compound as well as its active metabolites is essential for truly effective TDM. In this study, we developed and validated a method that simultaneously quantifies second- and third-generation EGFR-TKIs (afatinib, dacomitinib, and osimertinib) and the active metabolites of osimertinib, AZ5104 and AZ7550, in the human serum using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The clinical application of the method was also evaluated. The analytes were extracted from a 100 μL serum sample using a simple protein precipitation method and analyzed using LC-MS/MS. Excellent linearity of calibration curves was observed at ranges of 2.5–125.0 ng/mL for afatinib, 2.5–125.0 ng/mL for dacomitinib, 4.0–800.0 ng/mL for osimertinib, 1.0–125.0 ng/mL for AZ5104, and 2.5–125.0 ng/mL for AZ7550. The precision and accuracy were below 14.9% and within ± 14.9% of the nominal concentrations, respectively. The mean recovery was higher than 94.7% and the coefficient of variation (CV) was lower than 8.3%. The mean internal-standard normalized matrix factors ranged from 94.6 to 111.9%, and the CVs were lower than 9.7%. This analytical method met the acceptance criteria of the U.S. Food and Drug Administration guidelines. The method was also successfully applied to the analysis of 45 clinical samples; it supports the efficient and valuable analysis for TDM investigations of EGFR-TKIs.

  • Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study.

    Ogiwara T, Kawazoe H, Egami S, Hashimoto H, Saito Y, Sakiyama N, Ohe Y, Yamaguchi M, Furukawa T, Hara A, Hiraga Y, Jibiki A, Yokoyama Y, Suzuki S, Nakamura T

    Frontiers in oncology (Frontiers in Oncology)  11   770268 2021.11

    Research paper (scientific journal), Joint Work, Accepted

     View Summary

    Background: Nivolumab and pembrolizumab are the standard treatments for patients with advanced non-small-cell lung cancer (NSCLC). While there are reports on several inflammatory indices and the prognosis of patients with cancer, no study has combined baseline medication with the neutrophil-to-lymphocyte ratio (NLR) to predict clinical outcomes. This study investigated the efficacy of baseline medications plus NLR to predict the effectiveness of nivolumab and pembrolizumab in a real-world clinical setting. Methods: We conducted a single-center retrospective observational study of consecutive patients with advanced NSCLC who received nivolumab or pembrolizumab as first-line, second-line, or beyond treatment between December 2015 and November 2018 at the National Cancer Center Hospital in Japan. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method. The drug-based prognostic score for baseline medications plus NLR was weighed based on the regression β coefficients. The multivariable Cox proportional hazard model was used to assess the association between the prognostic score-stratified groups and survival outcomes. Results: In total, 259 patients were evaluated in this study. A prognostic score calculated from the baseline medications plus NLR was used to categorize the patients into good (score 0), intermediate (scores 1–2), and poor (scores 3–6) -prognosis groups. The multivariable Cox proportional hazard model revealed a significant association between the poor-prognosis group and reduced OS. The hazard ratio of OS was 1.75 (95% confidence interval: 1.07–2.99; P = 0.031). In contrast, no association between these prognosis groups and PFS was observed. Conclusions: The findings suggest that the baseline medications with nivolumab or pembrolizumab plus NLR could lead to progressively shorter survival outcomes in patients with advanced NSCLC and could be used as a prognostic index for poor outcomes. However, to ascertain the clinical application of these findings, these concomitant medications need further validation in a large-scale multicenter study.

  • Can Rubric-based Performance Evaluation Measure Students’ Performance Levels in Pharmacy Practice Experiences?: Based on the Revised Model Core Curriculum for Pharmaceutical Education.

    河添仁,鈴木小夜,平賀ゆい,横山雄太,地引綾,岩田紘樹,小林典子,藤本和子,中田英夫,青森達,山浦克典,中村智徳.

    医療薬学 ((一社)日本医療薬学会)  47 ( 9 ) 513 - 524 2021.09

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  1346-342X

     View Summary

    2019年度の5年次生144名を対象として、「薬学教育モデル・コアカリキュラム(平成25年度改訂版)」(改訂コアカリ)に準拠した薬局、病院実習におけるそれぞれの到達度の推移と、最終到達度(到達したパフォーマンスレベル)について、ルーブリック形式の概略評価スコアの総和を用いて評価し、指導薬剤師による他者評価と実習生の自己評価の相関性について検討した。その結果、薬局、病院実習とも、実習の進捗に伴って他者評価と自己評価は段階的に上昇し、すべての評価項目において各実習終了時の最終到達度は実習前期と比べて有意に上昇した。また、薬局、病院実習とも指導薬剤師と実習生の最終到達度の間に強い相関性を認めたが、「薬局実習」と「病院実習」との相関性は低かった。改訂コアカリに基づく薬局、病院実習において、実務実習生のパフォーマンスレベルはルーブリック形式の概略評価で測定可能である。

  • Design, synthesis, and monoamine oxidase inhibitory activity of (+)-cinchonaminone and its simplified derivatives.

    Sato Yuta, Oyobe Naoko, OGAWA Takao, Suzuki Sayo, Aoyama Hiroshi, Nakamura Tomonori, Fujioka Hiromichi, Shuto Satoshi and Arisawa Mitsuhiro.

    ACS Medicinal Chemistry Letters (ACS Medicinal Chemistry Letters)  12 ( 9 ) 1464 - 1469 2021.08

    Research paper (scientific journal), Joint Work, Accepted

     View Summary

    The absolute structure of an indole alkaloid (+)-cinchonaminone by total synthesis of both (+)-cinchonaminone and its enantiomer was determined. The main focus of the study was the enantioselective synthesis of both enantiomers of a chiral cis-3,4-disubstituted piperidine. We also evaluated monoamine oxidase (MAO) inhibitory activities of these enantiomers. Furthermore, its structurally simplified derivatives were synthesized that did not have any chiral center. Two of these derivatives showed stronger MAO inhibitory activities than that of (+)-cinchonaminone.

display all >>

Reviews, Commentaries, etc. 【 Display / hide

  • N-Arylsalsolinol誘導体の設計・合成・機能性評価 生成物選択的リガンドフリーBuchwald-Hartwig反応による合成

    山田 真希人, 林 邦忠, 文元 めぐみ, 鈴木 小夜, 布村 一人, Natchanun Sirimungkalakiti, 高橋 直行, 大木 裕太, 佐古 真, 村井 健一, 原田 和生, 荒井 雅吉, 中村 智徳, 春田 純一, 有澤 光弘

    日本薬学会年会要旨集 ((公社)日本薬学会)  142年会   26C - pm08S 2022.03

    ISSN  0918-9823

  • 【明日から使える免疫関連有害事象マネジメント 〜免疫チェックポイント阻害薬の看護ケア〜】免疫チェックポイント阻害薬の薬物動態を知る くすりを知ればケアがよくなる 免疫チェックポイント阻害薬の体内動態と有効性/毒性との関係

    鈴木 小夜, 中村 智徳

    がん看護 ((株)南江堂)  27 ( 2 ) 206 - 212 2022.02

    ISSN  1342-0569

     View Summary

    <文献概要>はじめに 免疫チェックポイント阻害薬(ICI)は使用実績も浅く,体内動態への影響要因や有効性や毒性との関連についてはいまだ不明な点も多いが,現時点での各ICIの体内動態の特徴,体内動態や曝露量(血中濃度)と反応性(有効性/毒性)についてまとめた(表1).体内動態および用量-反応曲線(E-R相関)の基本的な考え方については前稿を参照いただきたい.

  • 【明日から使える免疫関連有害事象マネジメント 〜免疫チェックポイント阻害薬の看護ケア〜】免疫チェックポイント阻害薬の薬物動態を知る くすりを知ればケアがよくなる 一般的な薬物と免疫チェックポイント阻害薬の体内動態 薬物は体内でどのような運命をたどって効果を発揮し体内から消失していくのか

    鈴木 小夜, 中村 智徳

    がん看護 ((株)南江堂)  27 ( 2 ) 200 - 205 2022.02

    ISSN  1342-0569

     View Summary

    <文献概要>はじめに 分子標的治療薬の一種である免疫チェックポイント阻害薬(ICI)によるがん治療は,薬物療法であると同時に免疫療法にも位置付けられ(図1),従来の細胞障害性抗がん薬とは治療戦略も体内動態も大きく異なる.がん細胞表面のPD-L1(programmed cell death-ligand 1),がん細胞を攻撃する細胞傷害性T細胞表面のPD-1(programmed cell death-1),CTLA-4(cytotoxic T-lymphocyte-associated protein 4)という,いずれもT細胞の攻撃力を弱める作用をもつ免疫チェックポイント分子をブロックして免疫力を強めるのがICIであり,具体的には抗PD-L1抗体,抗PD-1抗体,抗CTLA-4抗体である(図2).標的分子と結合する抗体薬であることがICIの体内動態を特徴づける.本稿では一般的な薬物体内動態の基本概念をベースにICIの体内動態および有効性や毒性との関係などについて概説する.

  • LC-MS/MSを用いた第二、三世代EGFR-TKI未変化体及び活性代謝物の血清中濃度同時測定法の構築と臨床に向けた検討

    石川 恵海, 横山 雄太, 千島 陽奈, 国吉 央城, 佐藤 到, 中谷 直喜, 中島 日出夫, 木村 元範, 袴田 潤, 末廣 直哉, 中田 英夫, 池村 辰之介, 平賀 ゆい, 地引 綾, 河添 仁, 村松 博, 鈴木 小夜, 中村 智徳

    TDM研究 ((一社)日本TDM学会)  38 ( 2 ) 187 - 187 2021.05

    ISSN  0911-1026

  • 慢性骨髄性白血病に対するチロシンキナーゼ阻害薬4剤のHPLC-PDAを用いた血清中濃度同時測定法の構築と臨床応用に向けた検討

    横山 雄太, 野澤 英士, 森田 美帆, 石川 恵海, 森 毅彦, 櫻井 政寿, 菊池 拓, 松木 絵里, 山崎 理絵, 平賀 ゆい, 地引 綾, 河添 仁, 鈴木 小夜, 中村 智徳

    TDM研究 ((一社)日本TDM学会)  38 ( 2 ) 177 - 177 2021.05

    ISSN  0911-1026

display all >>

Presentations 【 Display / hide

  • Application of the Professionalism Mini-Evaluation Exercise (P-MEX) for Assessing Japanese Students’ Medical Professionalism during Pharmacy Practice Experience (PPE) - Current Situation and Issues -

    Sayo Suzuki

    The10th Asian Association of Schools of Pharmacy (AASP) conference (AASP 2022) (Malaysia) , 

    2022.07

    Oral presentation (invited, special), The Asian Association of Schools of Pharmacy

  • Design, synthesis and functions of N-arylsalsolinol derivatives : Synthesis by product-selective ligand-free Buchwald-Hartwig amination.

    Makito Yamada, Bangzhong Lin, Megumi Fumimoto, Sayo Suzuki, Kazuto Nunomura, Sirimungkalakitti Natchanun, Naoyuki Takahashi, Yuuta Ohki, Makoto Sako, Kenichi Murai, Kazuo Harada, Masayoshi Arai, Tomonori Nakamura, Juniti Haruta, Mitsuhiro Arisawa.

    日本薬学会第142年会, 

    2022.03

    Oral presentation (general)

  • Implementing the Professionalism Mini-Evaluation Exercise (P-MEX) for assessing students’ medical professionalism during pharmacy practice experience (PPE) in Japan.

    Suzuki Sayo, Manabe Tsukasa, Matsuno Koju, Makiyama Hiroki, Kawamoto Shun, Maeda Tomoaki, Hirokawa Tatsuya, Kawai Yuki, Kikuyama Fumihiro, Jibiki Aya, Yokoyama Yuta, Kawazoe Hitoshi, Nakamura Tomonori.

    The 21st Asian Conference on Clinical Pharmacy 2022, 

    2022.02

    Poster presentation

  • Novel assay for simultaneous quantification of parent compounds and active metabolites of second-/third-generation EGFR-TKIs for clinical application.

    Ishikawa Emi, Yokoyama Yuta, Chishima Haruna, Kuniyoshi Ouki, Satou Itaru, Nakaya Naoki, Nakajima Hideo, Kimura Motonori, Hakamata Jun, Suehiro Naoya, Nakada Hideo, Ikemura Shinnosuke, Jibiki Aya, Kawazoe Hitoshi, Muramatsu Hiroshi, Suzuki Sayo, Nakamura Tomonori.

    The 21st Asian Conference on Clinical Pharmacy 2022, 

    2022.02

    Symposium, workshop panel (public)

  • Trends in the use of antidiabetic drugs for glucocorticoid-induced diabetes mellitus in a large-scale hospital database in Japan.

    Jibiki Aya, Kuji Moeka, Yokoyama Yuta, Kawazoe Hitoshi, Suzuki Sayo, Nakamura Tomonori.

    The 21st Asian Conference on Clinical Pharmacy 2022, 

    2022.02

    Poster presentation

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • The sensitivity to anticancer drugs in special population patients: Effect of an increase in blood bile acid concentration and mechanism analysis.

    2020.04
    -
    2023.03

    Japan Society for the Promotion of Science; Ministry of Education, Culture, Sports, Science and Technology (MEXT), Grant-in-Aid for Scientific Research, Sayo Suzuki, Tomonori Nakamura, Grant-in-Aid for Scientific Research (C) , Research grant, Principal investigator

     View Summary

    個々の患者の薬剤反応性に基づく治療の個別化は、がんの治療成績向上、患者の生活の質向上に不可欠である。本研究では、近年、がん細胞の生存と遺伝子レベルでの関わりが注目されている胆汁酸に着目し、例えば肝機能障害など血液中の胆汁酸が上昇するような病態が、がん細胞の増殖や抗がん剤反応性に与える影響、そのメカニズムについてがん細胞やがん細胞移植動物を用いて検討する。これにより、患者個々の病態に合わせた適切な抗がん剤の選択、効果的かつ安全ながん薬物治療の実現を目的とする。

  • Effect of bile acid with elevated levels in human serum on cancer cell proliferation and sensitivity to anticancer drugs.

    2017.04
    -
    2020.03

    Keio University, Grant-in-Aid for Scientific Research, Sayo Suzuki, Grant-in-Aid for Scientific Research (C), Research grant, Principal investigator

     View Summary

    Recently, many standard-of-care chemotherapy regimens have been established and new approaches to improve the prevention and early detection of cancer have also been developed. However, unfortunately, they leave much to be desired.
    In this study, we focused on the cancer treatments of patients with conditions like cholestasis. As a first step of this study, we mainly used several human cancer cells and deoxycholate (DCA) or chenodeoxycholate (CDCA) which are components in bile acids. We showed that DCA and / or CDCA with concentrations corresponding to elevated serum levels in such as cholestasis or biliary obstruction by tumors enhanced cell proliferation and / or decreased sensitivity to anticancer drugs depending on the kinds of cancer cells and conditions of bile acids exposure.

  • COX阻害薬の特性とがん細胞のCOX阻害特性に基づく抗腫瘍効果予測に関する研究

    2016.04
    -
    2017.03

    慶應義塾, Keio Gijuku Academic Development Funds, Research grant, Principal investigator

  • COX阻害薬の特性とがん細胞のCOX阻害特性に基づく抗腫瘍効果予測に関する研究

    2015.04
    -
    2016.03

    慶應義塾, Keio Gijuku Academic Development Funds, Research grant, Principal investigator

  • COX阻害薬の特性とがん細胞のCOX阻害特性に基づく抗腫瘍効果予測に関する研究

    2014.04
    -
    2015.03

    慶應義塾, Keio Gijuku Academic Development Funds, Research grant, Principal investigator

display all >>

Intellectual Property Rights, etc. 【 Display / hide

  • Method for determining sensitivity to anticancer agent.

    Date applied: PCT/JP2010/069362  2010.10 

    Date issued: EP 2495568 B1  2018.08

    Patent, Joint

  • METHOD FOR DETERMINING SENSITIVITY TO AN ANTICANCER AGENT.

    Date applied: 特願2011-538506  2010.10 

    Date issued: 特許第5548693号  2014.05

    Patent, Joint

  • METHOD FOR DTERMINATION OF SENSITIVITY TO ANTI-CANCER AGENT.

    Date applied: 特願2011-538507  2010.10 

    Date issued: 特許第5548694号  2014.05

    Patent, Joint

  • METHOD FOR DTERMINATION OF SENSITIVITY TO ANTI-CANCER AGENT.

    Date applied: 13/504,985  2010.10 

    Date issued: US 8,765,713 B2  2014.07

    Patent, Joint

  • 谷川原祐介

    Date applied: 201080049197. 8  2010.10 

    Date issued: ZL 2010 8 0049197.8  2016.03

    Patent, Joint

display all >>

Awards 【 Display / hide

  • Award for Encouragement of Educational Research

    2022.05, Japan Society for Pharmaceutical Education, Research for enhancing the learning effect of pharmaceutical practice experience and cultivating medical professionalism of pharmacy students through a metacognitive approach.

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • Best Poster Presenter <Student>

    Kikuyama Fumihiro, Sayo Suzuki, et al., 2022.02, The 21st Asian Conference on Clinical Pharmacy, Ingenol mebutate inhibits proliferation of pancreatic cancer cells at lower concentration than other established antitumor agents.

    Type of Award: Award from international society, conference, symposium, etc.

  • Best Oral Presenter <Student>

    Emi Ishikawa et al., 2022.02,  The 21st Asian Conference on Clinical Pharmacy, Novel assay for simultaneous quantification of parent compounds and active metabolites of second-/third-generation EGFR-TKIs for clinical application.

    Type of Award: Award from international society, conference, symposium, etc.

  • 学生優秀発表賞

    真鍋司, 鈴木小夜, 松野昂, 地引, 横山雄, 河添, 中村智徳, 2021.08, 第6回日本薬学教育学会大会, P-MEXによる薬局実務実習生のプロフェッショナリズム評価における評価者の設定と実用可能性―評価者の職種による影響の検討―

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 若手優秀演題賞

    石川恵海, 横山雄太, 千島陽奈, 国吉央城, 佐藤 到, 中谷直喜, 中島日出夫, 木村元範, 袴田 潤, 末廣直哉, 中田英夫, 池村辰之介, 平賀ゆい, 地引 綾, 河添 仁, 村松 博, 鈴木小夜, 中村智徳., 2021.06, 第37回日本TDM学会・学術大会, LC-MS/MS を用いた第二、三世代EGFR-TKI 未変化体及び活性代謝物の血清中濃度同時測定法の構築と臨床に向けた検討

    Type of Award: Award from Japanese society, conference, symposium, etc.

display all >>

 

Courses Taught 【 Display / hide

  • STUDY OF MAJOR FIELD: (PHARMACEUTICAL CARE SCIENCES)

    2022

  • SEMINAR: (PHARMACEUTICAL CARE SCIENCES)

    2022

  • RESEARCH FOR BACHELOR'S THESIS 1

    2022

  • PRIOR LEARNING FOR CLINICAL PRACTICE 3

    2022

  • PRIOR LEARNING FOR CLINICAL PRACTICE 1

    2022

display all >>

Educational Activities and Special Notes 【 Display / hide

  • 第61回 日本薬学会・中国四国支部学術大会 シンポジウム「臨床で活躍する薬剤師教育の現状ととりくみ」(仮題)

    2022.11

    , Lecture at Education Method and Practice

  • 「薬学教育における医療人プロフェッショナリズム教育について考える」.シンポジウム45「次期改訂薬学教育モデル・コア・カリキュラムの「臨床薬学」を充実させるために」.第32回 日本医療薬学会年会.

    2022.09

    , Lecture at Education Method and Practice

  • 「メタ認知的アプローチに基づいた臨床実習の学修効果向上および薬学生のプロフェッショナリズム醸成に関する研究」.2021年度日本薬学教育学会 教育研究奨励賞・受賞講演.第7回 日本薬学教育学会大会.

    2022.08

    , Lecture at Education Method and Practice

  • 「薬のエキスパートが活躍するさまざまな世界と社会貢献から薬学教育を考えるから薬学で学ぶ意義、そしてなぜ研究をするのか?~ 」医療薬学フォーラム2022/第30回クリニカルファーマシーシンポジウム「薬学教育」オーガナイザー

    2022.07

    , Lecture at Education Method and Practice

  • 日本医療薬学会 第2回 臨床研究セミナー「連携して臨床研究を進めよう」

    2022.04

    , Lecture at Education Method and Practice

display all >>

 

Social Activities 【 Display / hide

  • 「新薬紹介」日本薬剤師会雑誌

    公益社団法人 日本薬剤師会

    2021.06
    -
    Present
  • University of Southern California Marshall School of Business GSBA 580 C – PRIME Japan 2019 Japanese Women in Business

    University of Southern California Marshall School of Business

    2019.05
  • The Annual Overseas Pharmacy Internship Presentation on February 2nd, 2019

    2019.01
  • University of Southern California Marshall School of Business GSBA 580 C – PRIME Japan 2018 Japanese Women in Business

    University of Southern California Marshall School of Business

    2018.05
  • 「Oxalipltinの神経系細胞障害に対するanthraquinone系化合物emodinによる細胞保護効果」Nanion・東京女子医大 イオンチャネルフォーラム 2017~オートパッチクランプ技術とその発展~.

    Nanion, 東京女子医大 イオンチャネルフォーラム 2017~オートパッチクランプ技術とその発展~, 

    2017.07

display all >>

Media Coverage 【 Display / hide

  • 「ルーブリック評価,薬局・病院実習でトライアル実施 日本薬学教育学会大会で報告」薬事日報.

    薬事日報 (2017年9月6日(水)第11917号(1面)) , 2017.09

  • 将来を考えるお仕事ガイド-医療に関わるお仕事「薬剤師」.

    Z-KAI, Azest, 2014.02

Memberships in Academic Societies 【 Display / hide

  • American Association of Cancer Research, 

    2006
    -
    Present
  • International Association of Therapeutic Drug Monitoring and Clinical Toxicology, 

    2016
    -
    Present
  • Asian Association of School of Pharmacy, 

    2021.01
    -
    Present
  • Japanese Cancer Association, 

    2005
    -
    Present
  • Japan Society of Clinical Oncology, 

    2017
    -
    Present

display all >>

Committee Experiences 【 Display / hide

  • 2022.04
    -
    Present

    薬学臨床系教員連絡会 関東地区世話人, 薬学臨床系教員連絡会

  • 2021.06
    -
    Present

    日本薬剤師会 薬価基準検討会委員会(幹事), 公益社団法人 日本薬剤師会

  • 2021.02
    -
    Present

    日本薬学会 代議員, 公益社団法人 日本薬学会

  • 2021.02
    -
    Present

    日本薬学会 関東支部幹事, 公益社団法人 日本薬学会

  • 2020.04
    -
    Present

    日本医療薬学会 研究推進委員会委員, 一般社団法人日本医療薬学会

display all >>